KA
CRSP icon

Kovack Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Kovack Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Buy
4,936
+50
+1% +$2.63K 0.01% 853
2026
Q1 		$233K Buy
4,886
+310
+7% +$16.4K 0.01% 863
2025
Q4 		$240K Buy
+4,576
New +$274K 0.01% 861
2021
Q3 		– Sell
-1,434
Closed -$232K – 708
2021
Q2 		$232K Buy
+1,434
New +$174K 0.03% 592

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kovack Advisors's CRSP Position: Q2 2026 in Review

Kovack Advisors increased its CRISPR Therapeutics (CRSP) stake by 1% in Q2 2026, buying an estimated $2.63K and bringing the position to 4,936 shares worth $269K. The position accounts for 0.01% of the portfolio, ranked #853.

Kovack Advisors first reported a position in CRSP in Q2 2021 and has held it in 4 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Kovack Advisors held 4,936 shares of CRISPR Therapeutics worth $269K as of Q2 2026.
  • Kovack Advisors bought 50 CRISPR Therapeutics shares in Q2 2026, an estimated $2.63K.
  • CRISPR Therapeutics made up 0.01% of Kovack Advisors's portfolio in Q2 2026, its #853 holding.
  • Kovack Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.